Clinical Trials Logo

Hematological Malignancies B clinical trials

View clinical trials related to Hematological Malignancies B.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02844491 Terminated - Clinical trials for Hematological Malignancies B

Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B

Epitopes-LNH01
Start date: January 22, 2013
Phase:
Study type: Observational

Cancer-specific splice variants gain significant interest as they generate neo-antigens, that could be targeted by immune cells. CD20, a membrane antigen broadly expressed in mature B cell lymphomas, is subject to an alternative splicing named Delta-CD20 leading to loss of membrane expression of the spliced isoform. The investigators group would now determine if it's possible, in patients with lymphoproliferative B, to detect the presence of a specific memory response to delta-CD20 peptides. If this memory response exists, it will confirm the interest of this antigen as a target for tumor immunotherapy.